JP2021516231A5 - - Google Patents
Info
- Publication number
- JP2021516231A5 JP2021516231A5 JP2020545351A JP2020545351A JP2021516231A5 JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5 JP 2020545351 A JP2020545351 A JP 2020545351A JP 2020545351 A JP2020545351 A JP 2020545351A JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound according
- alkyl
- substituted
- compound
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636831P | 2018-02-28 | 2018-02-28 | |
| US62/636,831 | 2018-02-28 | ||
| PCT/US2019/019936 WO2019169065A2 (en) | 2018-02-28 | 2019-02-28 | Wee1 kinase inhibitors and methods of treating cancer using the same |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021516231A JP2021516231A (ja) | 2021-07-01 |
| JPWO2019169065A5 JPWO2019169065A5 (https=) | 2022-03-09 |
| JP2021516231A5 true JP2021516231A5 (https=) | 2022-03-09 |
| JP7483620B2 JP7483620B2 (ja) | 2024-05-15 |
Family
ID=67805580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545351A Active JP7483620B2 (ja) | 2018-02-28 | 2019-02-28 | Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12220415B2 (https=) |
| EP (1) | EP3758706A4 (https=) |
| JP (1) | JP7483620B2 (https=) |
| AU (1) | AU2019227823B2 (https=) |
| CA (1) | CA3088997A1 (https=) |
| WO (1) | WO2019169065A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6692423B2 (ja) | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3654982A4 (en) | 2017-07-18 | 2021-04-14 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3758706A4 (en) | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF |
| MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| CN113939296A (zh) | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| MX2022007623A (es) * | 2019-12-20 | 2022-09-23 | Recurium Ip Holdings Llc | Combinaciones. |
| AU2020404995A1 (en) * | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| CN113402520A (zh) * | 2020-03-16 | 2021-09-17 | 中国科学院上海药物研究所 | Wee1蛋白降解剂 |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| JP2024520969A (ja) * | 2021-05-28 | 2024-05-28 | 江蘇天士力帝益薬業有限公司 | Ｗｅｅ１阻害剤とその用途 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB884151A (en) * | 1957-12-06 | 1961-12-06 | Ciba Ltd | New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| NZ620000A (en) * | 2009-03-11 | 2015-07-31 | Auckland Uniservices Ltd | Prodrug forms of kinase inhibitors and their use in cancer therapy |
| BR112012004720B1 (pt) * | 2009-09-02 | 2021-06-29 | Auckland Uniservices Limited | Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6692423B2 (ja) * | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| CN108341830B (zh) | 2017-01-22 | 2021-03-02 | 广东东阳光药业有限公司 | 噻吩并嘧啶衍生物及其在药物中的应用 |
| WO2018133829A1 (zh) * | 2017-01-23 | 2018-07-26 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
| CA3071405A1 (en) | 2017-08-01 | 2019-02-07 | Recurium Ip Holdings, Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs |
| EP3758706A4 (en) | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF |
-
2019
- 2019-02-28 EP EP19760397.0A patent/EP3758706A4/en not_active Withdrawn
- 2019-02-28 JP JP2020545351A patent/JP7483620B2/ja active Active
- 2019-02-28 CA CA3088997A patent/CA3088997A1/en active Pending
- 2019-02-28 US US16/975,818 patent/US12220415B2/en active Active
- 2019-02-28 AU AU2019227823A patent/AU2019227823B2/en active Active
- 2019-02-28 WO PCT/US2019/019936 patent/WO2019169065A2/en not_active Ceased
-
2024
- 2024-12-20 US US18/991,248 patent/US20250186447A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516231A5 (https=) | ||
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| JPWO2019169065A5 (https=) | ||
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| US11001564B2 (en) | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | |
| RU2021103727A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| CN107406417A (zh) | 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物 | |
| JP2012501312A5 (https=) | ||
| JP2015530975A5 (https=) | ||
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| JP2013501790A5 (https=) | ||
| JP2017502967A5 (https=) | ||
| JP2020507606A5 (https=) | ||
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| JPWO2022250170A5 (https=) | ||
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| WO2016205460A4 (en) | Polycyclic derivatives targeting ral gtpases and their therapeutical applications | |
| JP2018519332A5 (https=) | ||
| WO2016087490A1 (en) | Combination of pi3k-inhibitors | |
| CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
| WO2018158175A1 (en) | Combination of bub1 inhibitors | |
| CA3116230A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |